25 results on '"Carolo, G."'
Search Results
2. Multi-Criteria Decision Analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage
- Author
-
De Nardo, Pasquale, primary, Gentilotti, Elisa, additional, Mazzaferri, Fulvia, additional, Cremonini, Eleonora, additional, Hansen, Paul, additional, Goossens, Herman, additional, Tacconelli, Evelina, additional, Durante Mangoni, E., additional, Florio, L.L., additional, Zampino, R., additional, Mele, F., additional, Gentile, I., additional, Pinchera, B., additional, Coppola, N., additional, Pisaturo, M., additional, Luzzati, R., additional, Petrosillo, N., additional, Nicastri, E., additional, Corpolongo, A., additional, Cataldo, M.A., additional, D’Abramo, A., additional, Maffongelli, G., additional, Scorzolini, L., additional, Palazzolo, C., additional, Boumis, E., additional, Pan, A., additional, D’Arminio Monforte, A., additional, Bai, F., additional, Antinori, S., additional, De Rosa, F.G., additional, Corcione, S., additional, Lupia, T., additional, Pinna, S.M., additional, Scabini, S., additional, Canta, F., additional, Belloro, S., additional, Bisoffi, Z., additional, Angheben, A., additional, Gobbi, F., additional, Turcato, E., additional, Ronzoni, N., additional, Moro, L., additional, Calabria, S., additional, Rodari, P., additional, Bertoli, G., additional, Marasca, G., additional, Puoti, M., additional, Gori, A., additional, Bandera, A., additional, Mangioni, D., additional, Rizzi, M., additional, Castelli, F., additional, Montineri, A., additional, Coco, C.A., additional, Maresca, M., additional, Frasca, M., additional, Aquilini, D., additional, Vincenzi, M., additional, Lambertenghi, L., additional, De Rui, M.E., additional, Razzaboni, E., additional, Cattaneo, P., additional, Visentin, A., additional, Erbogasto, A., additional, Dalla Vecchia, I., additional, Coledan, I., additional, Vecchi, M., additional, Be, G., additional, Motta, L., additional, Zaffagnini, A., additional, Auerbach, N., additional, Del Bravo, P., additional, Azzini, A.M., additional, Righi, E., additional, Carrara, E., additional, Savoldi, A., additional, Sibani, M., additional, Lattuada, E., additional, Carolo, G., additional, Cordioli, M., additional, Soldani, F., additional, Pezzani, M.D., additional, Avallone, S., additional, Bruno, R., additional, Ricciardi, A., additional, Saggese, M.P., additional, and Malerba, G., additional
- Published
- 2020
- Full Text
- View/download PDF
3. HIV-proviral DNA and plasma-RNA sequencing for detection of drug resistance mutations in antiretroviral naive patients: P665
- Author
-
Parisi, S. G., Zazzi, M., Dal Bello, F., Manfrin, V., Carolo, G., Nicolini, G., Gatti, F., Boldrin, C., Franchin, E., and Palù, G.
- Published
- 2005
4. Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy
- Author
-
Pasulo, L., primary, Gambato, M., additional, Spinetti, A., additional, D’Ambrosio, R., additional, Puoti, M., additional, Ciancio, A., additional, Di Marco, V., additional, Calvaruso, V., additional, Colombatto, P., additional, Brunetto, M., additional, Schiavini, M., additional, Fabris, P., additional, Sacchi, P., additional, Gulminetti, R., additional, Carolo, G., additional, Scotton, P., additional, Pozzan, C., additional, Vinci, M., additional, Viganò, M., additional, Lombardi, A., additional, Bello, S. Lo, additional, Zuin, M., additional, Aghemo, A., additional, Rumi, M.G., additional, Carrara, M., additional, Manfrin, V., additional, Uberti-Foppa, C., additional, Panese, S., additional, Paon, V., additional, Pan, A., additional, Spinelli, O., additional, D’Arminio Monforte, A., additional, Colli, A., additional, Spinzi, G., additional, Russo, F.P., additional, Chemello, L., additional, Vincenzi, V., additional, Grossi, P., additional, Buscarini, E., additional, Cardaci, G., additional, Soria, A., additional, Menzaghi, B., additional, Mendeni, M., additional, Soffredini, R., additional, Colpani, M., additional, Zaltron, S., additional, Gori, A., additional, Del Poggio, P., additional, Giorgini, A., additional, Cologni, G., additional, Cartabellotta, F., additional, Di Lorenzo, F., additional, Cacciola, I., additional, Albanese, A., additional, Di Rosolini, M.A., additional, Digiacomo, A., additional, Capretti, A., additional, Memoli, M., additional, Rossi, C., additional, Cavalletto, L., additional, Capra, F., additional, Colombo, A.E., additional, Dibenedetto, C., additional, Magni, C.F., additional, Noventa, F., additional, Lampertico, P., additional, Castelli, F., additional, Alberti, A., additional, and Fagiuoli, S., additional
- Published
- 2019
- Full Text
- View/download PDF
5. Long-term liver function changes and related risk factors after direct-acting antiviral therapy in HCV-infected cirrhotic patients: results from a prospective web-based regional platform
- Author
-
Russo, F.P., primary, Gambato, M., additional, Romano, A., additional, Piovesana, S., additional, Cattelan, A., additional, Bello, Lo, additional, Rossi, C., additional, Vanin, V., additional, Panese, S., additional, Franceschet, I., additional, Pozzan, C., additional, Paon, V., additional, Carolo, G., additional, Vincenzi, V., additional, Chemello, L., additional, Noventa, F., additional, Angeli, P., additional, Burra, P., additional, and Alberti, A., additional
- Published
- 2019
- Full Text
- View/download PDF
6. Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients
- Author
-
Gambato, M., primary, Spinetti, A., additional, Pasulo, L., additional, D’ambrosio, R., additional, Puoti, M., additional, Schiavini, M., additional, Fabris, P., additional, Sacchi, P., additional, Gulminetti, R., additional, Carolo, G., additional, Scotton, P., additional, Franceschet, I., additional, Vinci, M., additional, Viganò, M., additional, Lobello, S., additional, Zuin, M.G., additional, Aghemo, A., additional, Rumi, M., additional, Carrara, M., additional, Manfrin, V., additional, Uberti-Foppa, C., additional, Panese, S., additional, Cattelan, F., additional, Paon, V., additional, Pan, A., additional, Spinelli, O., additional, Monforte, A. D’arminio, additional, Colli, A., additional, Spinzi, G., additional, Russo, F.P., additional, Chemello, L., additional, Vincenzi, V., additional, Grossi, P.A., additional, Buscarini, E., additional, Cardaci, G., additional, Soria, A., additional, Menzaghi, B., additional, Mendeni, M., additional, Degasperi, E., additional, Soffredini, R., additional, Colpani, M., additional, Comi, L., additional, Zuccaro, V., additional, Zaltron, S., additional, Gori, A., additional, Del Poggio, P., additional, Giorgini, A., additional, Capretti, A., additional, Memoli, M., additional, Pigozzi, M.G., additional, Rossi, M.C., additional, Cavalletto, L., additional, Capra, F., additional, Colombo, A., additional, Dibenedetto, C., additional, Landonio, S., additional, Noventa, F., additional, Lampertico, P., additional, Castelli, F., additional, Alberti, A., additional, and Fagiuoli, S., additional
- Published
- 2019
- Full Text
- View/download PDF
7. Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks
- Author
-
Degasperi, E., primary, Spinetti, A., additional, Lombardi, A., additional, Landonio, S., additional, Scotton, P., additional, Pasulo, L., additional, Carlotto, A., additional, Giorgini, A., additional, Pozzoni, P., additional, Angeli, P., additional, Carrara, M., additional, Puoti, M., additional, Gatti, F., additional, Carolo, G., additional, Vinci, M., additional, Zoncada, A., additional, Bonfanti, P., additional, Aghemo, A., additional, Soria, A., additional, Centenaro, R., additional, Maggiolo, F., additional, Russo, F.P., additional, Rovere, P., additional, Piovesan, S., additional, Capra, F., additional, Viviani, F., additional, Morini, L., additional, Soffredini, R., additional, Carriero, C., additional, Paolucci, S., additional, Noventa, F., additional, Alberti, A., additional, Lampertico, P., additional, and Fagiuoli, S., additional
- Published
- 2019
- Full Text
- View/download PDF
8. Hepatitis C patients: Resilience and vulnerability for depression and anxiety
- Author
-
Fasani, G., primary, Tomassi, S., additional, Bonetto, C., additional, Ruggeri, M., additional, Rattin, M., additional, Corrias, M., additional, Carolo, G., additional, and Tosato, S., additional
- Published
- 2018
- Full Text
- View/download PDF
9. Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network
- Author
-
Invernizzi, F., primary, Pasulo, L., additional, Aghemo, A., additional, Puoti, M., additional, Zaltron, S., additional, Maggiolo, F., additional, Rizzardini, G., additional, Fargion, S., additional, Sacchi, P., additional, Gulminetti, R., additional, Zuin, M., additional, Quirino, T., additional, Rumi, M.G., additional, Pan, A., additional, Grossi, P., additional, Rossini, A., additional, Corbellini, A., additional, Uberti Foppa, C., additional, Belli, L., additional, Piovesan, S., additional, Angeli, P., additional, Chemello, L., additional, Russo, F.P., additional, Burra, P., additional, Vincenzi, V., additional, Cattelan, A.M., additional, Carolo, G., additional, Capra, F., additional, Carlotto, G., additional, Rovere, P.A., additional, Lobello, S., additional, Scotton, P., additional, Panese, S., additional, Fabris, P., additional, Alberti, A., additional, Lampertico, P., additional, and Fagiuoli, S., additional
- Published
- 2018
- Full Text
- View/download PDF
10. Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group
- Author
-
Degasperi, E., primary, Pasulo, L., additional, Aghemo, A., additional, Puoti, M., additional, Zaltron, S., additional, Maggiolo, F., additional, Rizzardini, G., additional, Fargion, S., additional, Sacchi, P., additional, Gulminetti, R., additional, Zuin, M., additional, Quirino, T., additional, Rumi, M.G., additional, Pan, A., additional, Grossi, P., additional, Rossini, A., additional, Corbellini, A., additional, Uberti Foppa, C., additional, Colli, A., additional, Piovesan, S., additional, Angeli, P., additional, Chemello, L., additional, Russo, F.P., additional, Burra, P., additional, Vincenzi, V., additional, Cattelan, A.M., additional, Carolo, G., additional, Capra, F., additional, Carlotto, G., additional, Rovere, P.A., additional, Lobello, S., additional, Scotton, P., additional, Panese, S., additional, Fabris, P., additional, Alberti, A., additional, Lampertico, P., additional, and Fagiuoli, S., additional
- Published
- 2018
- Full Text
- View/download PDF
11. Interaction between Levothyroxine and Indinavir in a Patient with HIV Infection
- Author
-
Lanzafame, M., Trevenzoli, M., Faggian, F., Marcati, P., Gatti, F., Carolo, G., and Concia, E.
- Published
- 2002
- Full Text
- View/download PDF
12. Cinetica di scomparsa delle mutazioni archiviate in corso di GART
- Author
-
Mazzi, R, Parisi, Sg, Sarmati, L, Carolo, G, Gatti, F, Nicastri, E, Montano, M, Concia, Ercole, and Andreoni, M.
- Subjects
GART ,cinetica ,mutazioni - Published
- 2003
13. Ginecomastia in 12 pazienti in trattamento con terapia antiretrovirale
- Author
-
Allegranzi, Benedetta, Mazzi, R, Gatti, F, Carolo, G, and Concia, Ercole
- Subjects
ginecomastia ,terapia antiretrovirale - Published
- 2001
14. Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS [1]
- Author
-
Mazzi, R, Parisi, S, Sarmati, L, Uccella, I, Nicastri, E, Carolo, G, Gatti, F, Concia, E, and Andreoni, M
- Subjects
treatment planning ,Skin Neoplasms ,stavudine ,Settore MED/17 - Malattie Infettive ,letter ,Kaposi ,cidofovir ,vincristine ,acquired immune deficiency syndrome ,Antiviral Agents ,immune response ,saquinavir ,Cytosine ,Organophosphorus Compounds ,vinblastine ,case report ,Humans ,human ,Viral ,Viremia ,Human herpesvirus 8 ,Herpesvirus 8 ,alpha interferon ,didanosine ,zalcitabine ,disease association ,disease course ,drug efficacy ,herpes ,Human immunodeficiency virus ,Kaposi sarcoma ,pathogenesis ,priority journal ,viremia ,AIDS-Related Opportunistic Infections ,Disease Progression ,DNA, Viral ,Herpesvirus 8, Human ,Phosphonic Acids ,Sarcoma, Kaposi ,Treatment Outcome ,Sarcoma ,DNA - Published
- 2001
15. P1466 Comamonas testosteroni spondylodiscitis
- Author
-
Carolo, G., primary, Ganau, M., additional, De Micheli, E., additional, Gerosa, M., additional, and Solbiati, M., additional
- Published
- 2007
- Full Text
- View/download PDF
16. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure
- Author
-
Elisabetta, Degasperi, Angiola, Spinetti, Andrea, Lombardi, Simona, Landonio, Maria Cristina, Rossi, Luisa, Pasulo, Pietro, Pozzoni, Alessia, Giorgini, Paolo, Fabris, Antonietta, Romano, Lorenzo, Lomonaco, Massimo, Puoti, Maria, Vinci, Federico, Gatti, Giada, Carolo, Alessia, Zoncada, Paolo, Bonfanti, Russo, FRANCESCO PAOLO, Alessio, Aghemo, Alessandro, Soria, Riccardo, Centenaro, Franco, Maggiolo, Pierangelo, Rovere, Francesca, Pasin, Veronica, Paon, Giovanni, Faggiano, Alessandro, Vario, Glenda, Grossi, Roberta, Soffredini, Canio, Carriero, Stefania, Paolucci, Franco, Noventa, Alfredo, Alberti, Pietro, Lampertico, Stefano, Fagiuoli, NAVIGATORE-Lombardia and Veneto Study Groups, Degasperi, E, Spinetti, A, Lombardi, A, Landonio, S, Rossi, M, Pasulo, L, Pozzoni, P, Giorgini, A, Fabris, P, Romano, A, Lomonaco, L, Puoti, M, Vinci, M, Gatti, F, Carolo, G, Zoncada, A, Bonfanti, P, Russo, F, Aghemo, A, Soria, A, Centenaro, R, Maggiolo, F, Rovere, P, Pasin, F, Paon, V, Faggiano, G, Vario, A, Grossi, G, Soffredini, R, Carriero, C, Paolucci, S, Noventa, F, Alberti, A, Lampertico, P, and Fagiuoli, S
- Subjects
0301 basic medicine ,Liver Cirrhosis ,Male ,Sofosbuvir ,Sustained Virologic Response ,Resistance ,Hepacivirus ,Viral Nonstructural Proteins ,medicine.disease_cause ,Direct-acting antiviral ,Direct-acting antivirals ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,Risk Factors ,Sulfonamides ,Liver Neoplasms ,Hepatitis C ,Middle Aged ,Drug Combinations ,Treatment Outcome ,Italy ,Hepatocellular carcinoma ,HCV ,RAS ,Retreatment ,RNA, Viral ,030211 gastroenterology & hepatology ,Female ,medicine.drug ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Macrocyclic Compounds ,Anemia ,Voxilaprevir ,Hepatitis C virus ,Antiviral Agents ,Heterocyclic Compounds, 4 or More Rings ,03 medical and health sciences ,Internal medicine ,Drug Resistance, Viral ,medicine ,Humans ,Intention-to-treat analysis ,Hepatology ,business.industry ,Ribavirin ,Hepatitis C, Chronic ,medicine.disease ,030104 developmental biology ,chemistry ,Carbamates ,business - Abstract
Background & Aims Sofosbuvir/velpatasivr/voxilaprevir (SOF/VEL/VOX) is approved for retreatment of patients with HCV and a previous failure on direct-acting antivirals (DAAs), however real-life data are limited. The aim of this study was to assess the effectiveness and safety of SOF/VEL/VOX in a real-life setting. Methods All consecutive patients with HCV receiving SOF/VEL/VOX between May-October 2018 in 27 centers in Northern Italy were enrolled. Bridging fibrosis (F3) and cirrhosis (F4) were diagnosed by liver stiffness measurement: >10 and >13 kPa respectively. Sustained virological response (SVR) was defined as undetectable HCV-RNA 4 (SVR4) or 12 (SVR12) weeks after the end-of-treatment. Results A total of 179 patients were included: median age 57 (18–88) years, 74% males, median HCV-RNA 1,081,817 (482–25,590,000) IU/ml. Fibrosis stage was F0-F2 in 32%, F3 in 21%, F4 in 44%. HCV genotype was 1 in 58% (1b 33%, 1a 24%, 1nc 1%), 2 in 10%, 3 in 23% and 4 in 9%; 82% of patients carried resistance-associated substitutions in the NS3, NS5A or NS5B regions. Patients received SOF/VEL/VOX for 12 weeks, ribavirin was added in 22% of treatment schedules. Undetectable HCV-RNA was achieved by 74% of patients at week 4 and by 99% at week 12. Overall, 162/179 (91%) patients by intention to treat analysis and 162/169 (96%) by per protocol analysis achieved SVR12, respectively; treatment failures included 6 relapsers and 1 virological non-responder. Cirrhosis (p = 0.005) and hepatocellular carcinoma (p = 0.02) were the only predictors of treatment failure. Most frequent adverse events included fatigue (6%), hyperbilirubinemia (6%) and anemia (4%). Conclusions SOF/VEL/VOX is an effective and safe retreatment for patients with HCV who have failed on a previous DAA course in a real-life setting. Lay summary This is the largest European real-life study evaluating effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in a large cohort of consecutive patients with hepatitis C virus infection and a prior direct-acting antiviral failure, who were treated within the NAVIGATORE Lombardia and Veneto Networks, in Italy. This study demonstrated excellent effectiveness (98% and 96% sustained virological response rates at week 4 and 12, respectively) and an optimal safety profile of SOF/VEL/VOX. Cirrhosis and hepatocellular carcinoma onset were the only features associated with treatment failure.
- Published
- 2019
17. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis
- Author
-
Giada Carolo, Veronica Bernabucci, Luchino Chessa, Maria Luisa Russo, Giorgio Maria Saracco, Marzia Montalbano, Barbara Menzaghi, Giovanni Di Perri, Adriano Lazzarin, Silvia La Monica, Raffaele Bruno, Gian Ludovico Rapaccini, Mario U. Mondelli, Anna Maria Schimizzi, Caterina Pasquazzi, Maurizia Rossana Brunetto, Antonio Craxì, Filomena Morisco, Carmela Lo Guercio, Vania Giacomet, Alessia Giorgini, Mario Masarone, Francesca Paolo Russo, T. Zolfino, Vincenzo Sangiovanni, Alessia Ciancio, Antonella d'Arminio Monforte, Savino Bruno, E.M. Erne, Antonio Gasbarrini, Francesco Castelli, Sergio Novara, G. Nardone, Andrea De Luca, Claudio Maria Mastroianni, Gioacchino Angarano, Chiara Dentone, Renato Maserati, Anna Maria Piscaglia, Tiziana Quirino, Giuseppe Tarantino, M. Lichtner, Antonio Chirianni, Giuseppina Brancaccio, S. Paganin, Alfredo Alberti, Silvia Corradori, Edoardo G. Giannini, Carlo Torti, Chiara Boarini, Raffaele Cozzolongo, Marco Di Stefano, Alessandro Soria, Paolo Tundi, Giovanni Cassola, Debora Angrisani, Antonio Grieco, Cecilia Pravadelli, Giuliano Rizzardini, Roberto Gulminetti, Vincenzo Messina, Maria Rendina, Massimo Pirisi, Irene Cacciola, Roberto Ganga, Raffaella Lionetti, Paolo Calabrese, Laura Ponti, Filomena Simeone, Maurizio Russello, Monica Monti, Nicola Boffa, Pierluigi Tarquini, Franco Capra, Ivo Avancini, Domenico Sansonno, Stefano Fagiuoli, Michele Barone, Giacomo Vecchiet, Salvatore Rizzo, Carlo Federico Perno, Teresa Santantonio, Pierluigi Toniutto, Massimo Zuin, Nicola Caporaso, Alessandra Orlandini, Grazielle Marie Pigozzi, Martina Felder, Antonio Cristaudo, Roberto Cecere, Massimo Marignani, Vincenza Calvaruso, G. Abbati, Domenico Potenza, Maria Chiara Piras, Mario Rizzetto, Serena Cima, Marco delle Monache, Alessio Aghemo, D. Ieluzzi, Guglielmo Borgia, Giampaolo Corti, Paolo Poggio, Manuela Merli, Elena Danieli, Andrea Giacometti, Massimo Andreoni, Antonino Picciotto, Mario Angelico, Benedetta Canovari, Sara Piovesan, Anna Linda Zignego, Antonio Benedetti, Emanuele Durante, Erica Villa, Marcello Persico, Antonio Patrizio Termite, Barbara Coco, Maria Vinci, Lucio Boglione, Cristina Rossi, Paolo Angeli, Massimo Memoli, Maria Teresa Giordani, Massimo De Luca, Luisa Pasulo, Vincenzo Vullo, Mario Melazzini, Attilio Solinas, Pietro Gatti, Michele Guerra, Silvia Martini, Antonio Ascione, Massimo Puoti, Roberto Cauda, Giovanna Onnelli, Silvia Magnani, Salvatore Madonna, Giovanni Raimondo, Marco Tabone, Gloria Taliani, Dante Romagnoli, Aldo Marrone, Umberto Vespasiani Gentilucci, Luca Miele, Marcello Tavio, Andrea Antinori, Giampiero D'Offizi, Mirella Onofrio, Valentina Iodice, Lucio Cosco, Guido Piai, Luca Pani, Francesca Ceccherini Silberstein, Simona Montilla, Marco Lenzi, Luca Fontanella, Alessandro Federico, Carlo Ferrari, Giustino Parruti, Antonio Di Biagio, Gabriella Verucchi, Fabio Marsetti, Michele Milella, Maria Grazia Rumi, Antonio Izzi, Marco Marzioni, Francesca Donato, Vanni Borghi, Mariano Quartini, Massimo Colombo, Michele Imparato, Giovanni Battista Gaeta, P.L. Blanc, Alfredo Di Leo, Nicola Coppola, Alessandro Chiodera, Ivana Maida, Davide Campagnolo, Cinzia Antonini, Antonietta Romano, A. Gianstefani, Katia Falasca, Massimo Levrero, Gaetano Serviddio, Maria Paola Trotta, Olivia Morelli, Salvatore Petta, Elisabetta Teti, Maria Rita Parisi, Pietro Andreone, Ascione, Antonio, De Luca, Massimo, Melazzini, Mario, Montilla, Simona, Trotta, Maria Paola, Petta, Salvatore, Puoti, Massimo, Sangiovanni, Vincenzo, Messina, Vincenzo, Bruno, Savino, Izzi, Antonio, Villa, Erica, Aghemo, Alessio, Zignego, Anna Linda, Orlandini, Alessandra, Fontanella, Luca, Gasbarrini, Antonio, Marzioni, Marco, Giannini, Edoardo G., Craxì, Antonio, Abbati, Giuseppe, Alberti, Alfredo, Andreone, Pietro, Andreoni, Massimo, Angeli, Paolo, Angelico, Mario, Angarano, Gioacchino, Angrisani, Debora, Antinori, Andrea, Antonini, Cinzia, Avancini, Ivo, Barone, Michele, Bruno, Raffaele, Benedetti, Antonio, Bernabucci, Veronica, Blanc, Pier, Boarini, Chiara, Boffa, Nicola, Boglione, Lucio, Borghi, Vanni, Borgia, Guglielmo, Brancaccio, Giuseppina, Brunetto, Maurizia, Cacciola, Irene, Calabrese, Paolo, Calvaruso, Vincenza, Campagnolo, Davide, Canovari, Benedetta, Caporaso, Nicola, Capra, Franco, Carolo, Giada, Cassola, Giovanni, Castelli, Francesco, Cauda, Roberto, Silberstein, Francesca Ceccherini, Cecere, Roberto, Chessa, Luchino, Chiodera, Alessandro, Chirianni, Antonio, Ciancio, Alessia, Cima, Serena, Coco, Barbara, Colombo, Massimo, Coppola, Nicola, Corti, Giampaolo, Cosco, Lucio, Corradori, Silvia, Cozzolongo, Raffaele, Cristaudo, Antonio, Danieli, Elena, Monforte, Antonella D’Arminio, Monache, Marco delle, Del Poggio, Paolo, de Luca, Andrea, Dentone, Chiara, Di Biagio, Antonio, Di Leo, Alfredo, Di Perri, Giovanni, Di Stefano, Marco, D’Offizi, Giampiero, Donato, Francesca, Durante, Emanuele, Erne, Elke, Fagiuoli, Stefano, Falasca, Katia, Federico, Alessandro, Felder, Martina, Ferrari, Carlo, Gaeta, Giovanni Battista, Ganga, Roberto, Gatti, Pietro, Giacomet, Vania, Giacometti, Andrea, Gianstefani, Alice, Giordani, Maria, Giorgini, Alessia, Grieco, Antonio, Guerra, Michele, Gulminetti, Roberto, Ieluzzi, Donatella, Imparato, Michele, Iodice, Valentina, La Monica, Silvia, Lazzarin, Adriano, Lenzi, Marco, Levrero, Massimo, Lichtner, Myriam, Lionetti, Raffaella, Guercio, Carmela Lo, Madonna, Salvatore, Magnani, Silvia, Maida, Ivana, Marignani, Massimo, Marrone, Aldo, Marsetti, Fabio, Martini, Silvia, Masarone, Mario, Maserati, Renato, Mastroianni, Claudio Maria, Memoli, Massimo, Menzaghi, Barbara, Merli, Manuela, Miele, Luca, Milella, Michele, Mondelli, Mario, Montalbano, Marzia, Monti, Monica, Morelli, Olivia, Morisco, Filomena, Nardone, Gaetano, Novara, Sergio, Onnelli, Giovanna, Onofrio, Mirella, Paganin, Simona, Pani, Luca, Parisi, Maria Rita, Parruti, Giustino, Pasquazzi, Caterina, Pasulo, Luisa, Perno, Carlo Federico, Persico, Marcello, Piai, Guido, Picciotto, Antonino, Pigozzi, Grazielle Marie, Piovesan, Sara, Piras, Maria Chiara, Pirisi, Massimo, Piscaglia, Anna Maria, Ponti, Laura, Potenza, Domenico, Pravadelli, Cecilia, Quartini, Mariano, Quirino, Tiziana, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Rendina, Maria, Rizzardini, Giuliano, Rizzetto, Mario, Rizzo, Salvatore, Romagnoli, Dante, Romano, Antonietta, Rossi, Cristina, Rumi, Maria Grazia, Russello, Maurizio, Russo, Francesca Paolo, Russo, Maria Luisa, Sansonno, Domenico Ettore, Santantonio, Teresa Antonia, Saracco, Giorgio, Schimizzi, Anna Maria, Serviddio, Gaetano, Simeone, Filomena, Solinas, Attilio, Soria, Alessandro, Tabone, Marco, Taliani, Gloria, Tarantino, Giuseppe, Tarquini, Pierluigi, Tavio, Marcello, Termite, Antonio, Teti, Elisabetta, Toniutto, Pierluigi, Torti, Carlo, Tundi, Paolo, Vecchiet, Giacomo, Verucchi, Gabriella, Gentilucci, Umberto Vespasiani, Vinci, Maria, Vullo, Vincenzo, Zolfino, Teresa, Zuin, Massimo, Ascione, A, De Luca, M, Melazzini, M, Montilla, S, Trotta, M, Petta, S, Puoti, M, Sangiovanni, V, Messina, V, Bruno, S, Izzi, A, Villa, E, Aghemo, A, Zignego, A, Orlandini, A, Fontanella, L, Gasbarrini, A, Marzioni, M, Giannini, E, Craxi, A, Abbati, G, Alberti, A, Andreone, P, Andreoni, M, Angeli, P, Angelico, M, Angarano, G, Angrisani, D, Antinori, A, Antonini, C, Avancini, I, Barone, M, Bruno, R, Benedetti, A, Bernabucci, V, Blanc, P, Boarini, C, Boffa, N, Boglione, L, Borghi, V, Borgia, G, Brancaccio, G, Brunetto, M, Cacciola, I, Calabrese, P, Calvaruso, V, Campagnolo, D, Canovari, B, Caporaso, N, Capra, F, Carolo, G, Cassola, G, Castelli, F, Cauda, R, Silberstein, F, Cecere, R, Chessa, L, Chiodera, A, Chirianni, A, Ciancio, A, Cima, S, Coco, B, Colombo, M, Coppola, N, Corti, G, Cosco, L, Corradori, S, Cozzolongo, R, Cristaudo, A, Danieli, E, Monforte, A, Monache, M, Del Poggio, P, de Luca, A, Dentone, C, Di Biagio, A, Di Leo, A, Di Perri, G, Di Stefano, M, D'Offizi, G, Donato, F, Durante, E, Erne, E, Fagiuoli, S, Falasca, K, Federico, A, Felder, M, Ferrari, C, Gaeta, G, Ganga, R, Gatti, P, Giacomet, V, Giacometti, A, Gianstefani, A, Giordani, M, Giorgini, A, Grieco, A, Guerra, M, Gulminetti, R, Ieluzzi, D, Imparato, M, Iodice, V, La Monica, S, Lazzarin, A, Lenzi, M, Levrero, M, Lichtner, M, Lionetti, R, Guercio, C, Madonna, S, Magnani, S, Maida, I, Marignani, M, Marrone, A, Marsetti, F, Martini, S, Masarone, M, Maserati, R, Mastroianni, C, Memoli, M, Menzaghi, B, Merli, M, Miele, L, Milella, M, Mondelli, M, Montalbano, M, Monti, M, Morelli, O, Morisco, F, Nardone, G, Novara, S, Onnelli, G, Onofrio, M, Paganin, S, Pani, L, Parisi, M, Parruti, G, Pasquazzi, C, Pasulo, L, Perno, C, Persico, M, Piai, G, Picciotto, A, Pigozzi, G, Piovesan, S, Piras, M, Pirisi, M, Piscaglia, A, Ponti, L, Potenza, D, Pravadelli, C, Quartini, M, Quirino, T, Raimondo, G, Rapaccini, G, Rendina, M, Rizzardini, G, Rizzetto, M, Rizzo, S, Romagnoli, D, Romano, A, Rossi, C, Rumi, M, Russello, M, Russo, F, Russo, M, Sansonno, D, Santantonio, T, Saracco, G, Schimizzi, A, Serviddio, G, Simeone, F, Solinas, A, Soria, A, Tabone, M, Taliani, G, Tarantino, G, Tarquini, P, Tavio, M, Termite, A, Teti, E, Toniutto, P, Torti, C, Tundi, P, Vecchiet, G, Verucchi, G, Gentilucci, U, Vinci, M, Vullo, V, Zolfino, T, and Zuin, M
- Subjects
Cyclopropanes ,Liver Cirrhosis ,Male ,Cirrhosis ,Dasabuvir ,Elderly ,Ombitasvir ,Paritaprevir ,Aged ,80 and over ,Anilides ,Antiviral Agents ,Biomarkers ,Carbamates ,Female ,Hepacivirus ,Hepatitis C ,Chronic ,Humans ,Macrocyclic Compounds ,Ribavirin ,Ritonavir ,Sulfonamides ,Treatment Outcome ,Uracil ,Drug Therapy ,Combination ,Genotype ,Cirrhosis, Dasabuvir, Elderly, Ombitasvir, Paritaprevir, Microbiology (medical), Infectious Diseases ,Aged, 80 and over ,Hepatitis C, Chronic ,Drug Therapy, Combination ,Microbiology (medical) ,Infectious Diseases ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,2-Naphthylamine ,Medicine ,030212 general & internal medicine ,Valine ,General Medicine ,030211 gastroenterology & hepatology ,Macrocyclic Compound ,medicine.drug ,Human ,medicine.medical_specialty ,Proline ,Lactams, Macrocyclic ,Settore MED/12 - GASTROENTEROLOGIA ,Liver Cirrhosi ,Sulfonamide ,03 medical and health sciences ,Internal medicine ,Decompensation ,Hepatitis ,Antiviral Agent ,Cirrhosi ,Hepaciviru ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,Anilide ,Biomarker ,medicine.disease ,chemistry ,Carbamate ,business - Abstract
Purpose: To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65years. Methods: We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100mg) and twice-daily dasabuvir (250mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12weeks after the end of treatment (SVR12). Results: Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A multivariate analysis found albumin < 3.5g/dL (OR 2.04: 95% CI 1.0–4.2, p < 0.05) and hypertension (OR 4.6: 95% CI 2.3–9.2, p < 0.001) as variables independently associated with AE occurrence. The SVR12 was 95% (228/240). Multivariate analysis identified baseline bilirubin < 2mg/dL (OR 4.9: 95% CI 1.17–20.71, p = 0.029) as the only variable independently associated with SVR12. Conclusion: Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65.
- Published
- 2018
18. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
- Author
-
Petta, Salvatore, Marzioni, Marco, Russo, Pierluigi, Aghemo, Alessio, Alberti, Alfredo, ASCIONE, ANTONIO, Antinori, Andrea, Bruno, Raffaele, Bruno, Savino, Chirianni, Antonio, Gaeta, Giovanni Battista, Giannini, Edoardo G, Merli, Manuela, Messina, Vincenzo, Montilla, Simona, Perno, Carlo Federico, Puoti, Massimo, Raimondo, Giovanni, Rendina, Maria, Silberstein, Francesca Ceccherini, Villa, Erica, Zignego, Anna Linda, Pani, Luca, Craxì, Antonio, Tabone, Marco, Andreoni, Massimo, Teti, Elisabetta, Angelico, Mario, Persico, Marcello, Masarone, Mario, Chiodera, Aledssandro, Solinas, Attilio, delle Monache, Marco, Cecere, Roberto, Maria Schimizzi, Anna, Piovesan, Sara, Campagnolo, Davide, Chiara Piras, Maria, Zolfino, Teresa, Paolo Russo, Francesca, Morelli, Olivia, Sangiovanni, Vincenzo, Onofrio, Mirella, Iodice, Valentina, Izzi, Antonio, Pirisi, Massimo, Danieli, Elena, Vinci, Maria, Rizzardini, Giuliano, Fagiuoli, Stefano, Pasulo, Luisa, D'Arminio Monforte, Antonella, Zuin, Massimo, Giorgini, Alessia, Simeone, Filomena, Piali, Guido, Lo Guercio, Carmela, Federico, Alessandro, Brancaccio, Giuseppina, Marrone, Aldo, Abbati, Giuseppe, Boarini, Chiara, Borghi, Vanni, Bernabucci, Veronica, Corti, Giampaolo, Monti, Monica, Rizzetto, Mario, Martini, Silvia, Andreone, Pietro, Gianstefani, Alice, Lenzi, Marco, Verucchi, Gabriella, Toniutto, Pierluigi, Borgia, Guglielmo, Caporaso, Nicola, Morisco, Filomena, Nardone, Gaetano, Angrisani, Debora, Giacometti, Andrea, Benedetti, Antonio, Tarantino, Giuseppe, Marsetti, Fabio, Tavio, Marcello, Novara, Sergio, Antonia Santantonio, Teresa, Serviddio, Gaetano, Brunetto, Maurizia, Coco, Barbara, Angarano, Gioacchino, Milella, Michele, BARONE, MICHELE, Di Leo, Alfredo, Ettore Sansonno, Domenico, Cacciola, Irene, Boffa, Nicola, Saracco, Giorgio, Di Biagio, Antonio, Picciotto, Antonino, de Luca, Andrea, Calvaruso, Vincenza, Corradori, Silvia, Ferrari, Carlo, Orlandini, Alessandra, Maida, Ivana, Torti, Carlo, Chessa, Luchino, Felder, Martina, Vespasiani Gentilucci, Umberto, Angeli, Paolo, Romano, Antonietta, Ludovico Rapaccini, Gian, Miele, Luca, Cima, Serena, Luisa Russo, Maria, Cozzolongo, Raffaele, Onnelli, Giovanna, D'Offizi, Giampiero, Lionetti, Raffaella, Montalbano, Marzia, Guerra, Michele, Di Perri, Giovanni, Boglione, Lucio, Capra, Franco, Carolo, Giada, Ieluzzi, Donatella, Antonini, Cinzia, Termite, Antonio, Madonia, Salvatore, Tarquini, Pierluigi, Parruti, Giustino, Vecchiet, Giacomo, Falasca, Katia, Menzaghi, Barbara, Quirino, Tiziana, Dentone, Chiara, Maria Piscaglia, Anna, Rossi, Cristina, Giordani, Maria, Fontanella, Luca, Cassola, Giovanni, Russello, Maurizio, Cristaudo, Antonio, Giacomet, Vania, Colombo, Massimo, Donato, Francesca, Durante, Emanuele, Cosco, Lucio, Marignani, Massimo, Quartini, Mariano, Memoli, Massimo, Ganga, Roberto, Ponti, Laura, Soria, Alessandro, Grazia Rumi, Maria, Gulminetti, Roberto, Maserati, Renato, Mondelli, Mario, Lazzarin, Adriano, Rita Parisi, Maria, Canovari, Benedetta, Avancini, Ivo, Pravadelli, Cecilia, Blanc, Pier, Pasquazzi, Caterina, Maria Mastroianni, Claudio, Lichtner, Myriam, Distefano, Marco, Magnani, Silvia, Paganin, Simona, Erne, Elke, Gatti, Pietro, Tundi, Paolo, Calabrese, Paolo, Gasbarrini, Antonio, Grieco, Antonio, Coppola, Nicola, Del Poggio, Paolo, Levrero, Massimo, Talliani, Gloria, Vullo, Vincenzo, Cauda, Roberto, La Monica, Silvia, Potenza, Domenico, Rizzo, Salvatore, Castelli, Francesco, Marie Pigozzi, Grazielle, Ciancio, Alessia, Romagnoli, Dante, Barchetti, Federica, Ivanovic, Jelena, Longo, Olimpia, Petraglia, Sandra, Paola Trotta, Maria, NARDONE, GERARDO ANTONIO PIO, Petta, Salvatore, Marzioni, Marco, Russo, Pierluigi, Aghemo, Alessio, Alberti, Alfredo, Ascione, Antonio, Antinori, Andrea, Bruno, Raffaele, Bruno, Savino, Chirianni, Antonio, Gaeta, Giovanni Battista, Giannini, Edoardo G, Merli, Manuela, Messina, Vincenzo, Montilla, Simona, Perno, Carlo Federico, Puoti, Massimo, Raimondo, Giovanni, Rendina, Maria, Silberstein, Francesca Ceccherini, Villa, Erica, Zignego, Anna Linda, Pani, Luca, Craxì, Antonio, Tabone, Marco, Andreoni, Massimo, Teti, Elisabetta, Angelico, Mario, Persico, Marcello, Masarone, Mario, Chiodera, Aledssandro, Solinas, Attilio, delle Monache, Marco, Cecere, Roberto, Maria Schimizzi, Anna, Piovesan, Sara, Campagnolo, Davide, Chiara Piras, Maria, Zolfino, Teresa, Paolo Russo, Francesca, Morelli, Olivia, Sangiovanni, Vincenzo, Onofrio, Mirella, Iodice, Valentina, Izzi, Antonio, Pirisi, Massimo, Danieli, Elena, Vinci, Maria, Rizzardini, Giuliano, Fagiuoli, Stefano, Pasulo, Luisa, D'Arminio Monforte, Antonella, Zuin, Massimo, Giorgini, Alessia, Simeone, Filomena, Piali, Guido, Lo Guercio, Carmela, Federico, Alessandro, Brancaccio, Giuseppina, Marrone, Aldo, Abbati, Giuseppe, Boarini, Chiara, Borghi, Vanni, Bernabucci, Veronica, Corti, Giampaolo, Monti, Monica, Rizzetto, Mario, Martini, Silvia, Andreone, Pietro, Gianstefani, Alice, Lenzi, Marco, Verucchi, Gabriella, Toniutto, Pierluigi, Borgia, Guglielmo, Caporaso, Nicola, Morisco, Filomena, Nardone, Gaetano, Angrisani, Debora, Giacometti, Andrea, Benedetti, Antonio, Tarantino, Giuseppe, Marsetti, Fabio, Tavio, Marcello, Novara, Sergio, Antonia Santantonio, Teresa, Serviddio, Gaetano, Brunetto, Maurizia, Coco, Barbara, Angarano, Gioacchino, Milella, Michele, Barone, Michele, Di Leo, Alfredo, Ettore Sansonno, Domenico, Cacciola, Irene, Boffa, Nicola, Saracco, Giorgio, Di Biagio, Antonio, Picciotto, Antonino, de Luca, Andrea, Calvaruso, Vincenza, Corradori, Silvia, Ferrari, Carlo, Orlandini, Alessandra, Maida, Ivana, Torti, Carlo, Chessa, Luchino, Felder, Martina, Vespasiani Gentilucci, Umberto, Angeli, Paolo, Romano, Antonietta, Ludovico Rapaccini, Gian, Miele, Luca, Cima, Serena, Luisa Russo, Maria, Cozzolongo, Raffaele, Onnelli, Giovanna, D'Offizi, Giampiero, Lionetti, Raffaella, Montalbano, Marzia, Guerra, Michele, Di Perri, Giovanni, Boglione, Lucio, Capra, Franco, Carolo, Giada, Ieluzzi, Donatella, Antonini, Cinzia, Termite, Antonio, Madonia, Salvatore, Tarquini, Pierluigi, Parruti, Giustino, Vecchiet, Giacomo, Falasca, Katia, Menzaghi, Barbara, Quirino, Tiziana, Dentone, Chiara, Maria Piscaglia, Anna, Rossi, Cristina, Giordani, Maria, Fontanella, Luca, Cassola, Giovanni, Russello, Maurizio, Cristaudo, Antonio, Giacomet, Vania, Colombo, Massimo, Donato, Francesca, Durante, Emanuele, Cosco, Lucio, Marignani, Massimo, Quartini, Mariano, Memoli, Massimo, Ganga, Roberto, Ponti, Laura, Soria, Alessandro, Grazia Rumi, Maria, Gulminetti, Roberto, Maserati, Renato, Mondelli, Mario, Lazzarin, Adriano, Rita Parisi, Maria, Canovari, Benedetta, Avancini, Ivo, Pravadelli, Cecilia, Blanc, Pier, Pasquazzi, Caterina, Maria Mastroianni, Claudio, Lichtner, Myriam, Distefano, Marco, Magnani, Silvia, Paganin, Simona, Erne, Elke, Gatti, Pietro, Tundi, Paolo, Calabrese, Paolo, Gasbarrini, Antonio, Grieco, Antonio, Coppola, Nicola, Del Poggio, Paolo, Levrero, Massimo, Talliani, Gloria, Vullo, Vincenzo, Cauda, Roberto, La Monica, Silvia, Potenza, Domenico, Rizzo, Salvatore, Castelli, Francesco, Marie Pigozzi, Grazielle, Ciancio, Alessia, Romagnoli, Dante, Barchetti, Federica, Ivanovic, Jelena, Longo, Olimpia, Petraglia, Sandra, Paola Trotta, Maria, Petta, S., Marzioni, M., Russo, P., Aghemo, A., Alberti, A., Ascione, A., Antinori, A., Bruno, R., Bruno, S., Chirianni, A., Gaeta, G., Giannini, E., Merli, M., Messina, V., Montilla, S., Perno, C., Puoti, M., Raimondo, G., Rendina, M., Silberstein, F., Villa, E., Zignego, A., Pani, L., Craxi, A., Tabone, M., Andreoni, M., Teti, E., Angelico, M., Persico, M., Masarone, M., Chiodera, A., Solinas, A., delle Monache, M., Cecere, R., Maria Schimizzi, A., Piovesan, S., Campagnolo, D., Chiara Piras, M., Zolfino, T., Paolo Russo, F., Morelli, O., Sangiovanni, V., Onofrio, M., Iodice, V., Izzi, A., Pirisi, M., Danieli, E., Vinci, M., Rizzardini, G., Fagiuoli, S., Pasulo, L., D'Arminio Monforte, A., Zuin, M., Giorgini, A., Simeone, F., Piali, G., Lo Guercio, C., Federico, A., Brancaccio, G., Marrone, A., Abbati, G., Boarini, C., Borghi, V., Bernabucci, V., Corti, G., Monti, M., Rizzetto, M., Martini, S., Andreone, P., Gianstefani, A., Lenzi, M., Verucchi, G., Toniutto, P., Borgia, G., Caporaso, N., Morisco, F., Nardone, G., Angrisani, D., Giacometti, A., Benedetti, A., Tarantino, G., Marsetti, F., Tavio, M., Novara, S., Antonia Santantonio, T., Serviddio, G., Brunetto, M., Coco, B., Angarano, G., Milella, M., Barone, M., Di Leo, A., Ettore Sansonno, D., Cacciola, I., Boffa, N., Saracco, G., Di Biagio, A., Picciotto, A., de Luca, A., Calvaruso, V., Corradori, S., Ferrari, C., Orlandini, A., Maida, I., Torti, C., Chessa, L., Felder, M., Vespasiani Gentilucci, U., Angeli, P., Romano, A., Ludovico Rapaccini, G., Miele, L., Cima, S., Luisa Russo, M., Cozzolongo, R., Onnelli, G., D'Offizi, G., Lionetti, R., Montalbano, M., Guerra, M., Di Perri, G., Boglione, L., Capra, F., Carolo, G., Ieluzzi, D., Antonini, C., Termite, A., Madonia, S., Tarquini, P., Parruti, G., Vecchiet, G., Falasca, K., Menzaghi, B., Quirino, T., Dentone, C., Maria Piscaglia, A., Rossi, C., Giordani, M., Fontanella, L., Cassola, G., Russello, M., Cristaudo, A., Giacomet, V., Colombo, M., Donato, F., Durante, E., Cosco, L., Marignani, M., Quartini, M., Memoli, M., Ganga, R., Ponti, L., Soria, A., Grazia Rumi, M., Gulminetti, R., Maserati, R., Mondelli, M., Lazzarin, A., Rita Parisi, M., Canovari, B., Avancini, I., Pravadelli, C., Blanc, P., Pasquazzi, C., Maria Mastroianni, C., Lichtner, M., Distefano, M., Magnani, S., Paganin, S., Erne, E., Gatti, P., Tundi, P., Calabrese, P., Gasbarrini, A., Grieco, A., Coppola, N., Del Poggio, P., Levrero, M., Talliani, G., Vullo, V., Cauda, R., La Monica, S., Potenza, D., Rizzo, S., Castelli, F., Marie Pigozzi, G., Ciancio, A., Romagnoli, D., Barchetti, F., Ivanovic, J., Longo, O., Petraglia, S., Paola Trotta, M., Savino, Bruno, Nardone, GERARDO ANTONIO PIO, Petta, S, Marzioni, M, Russo, P, Aghemo, A, Alberti, A, Ascione, A, Antinori, A, Bruno, R, Bruno, S, Chirianni, A, Gaeta, G, Giannini, E, Merli, M, Messina, V, Montilla, S, Perno, C, Puoti, M, Raimondo, G, Rendina, M, Silberstein, F, Villa, E, Zignego, A, Pani, L, Craxì, A, and Fagiuoli, S
- Subjects
Cyclopropanes ,Compassionate Use Trials ,Liver Cirrhosis ,Male ,chemistry.chemical_compound ,0302 clinical medicine ,2-Naphthylamine ,HCV, direct-acting antiviral, mixed cryoglobulinemia, RBV ,Anilides ,030212 general & internal medicine ,Longitudinal Studies ,Prospective Studies ,Chronic ,Adult ,Aged ,Antiviral Agents ,Carbamates ,Drug Therapy, Combination ,Female ,Genotype ,Hepatitis C, Chronic ,Humans ,Macrocyclic Compounds ,Middle Aged ,Ribavirin ,Ritonavir ,Sulfonamides ,Treatment Outcome ,Uracil ,Settore MED/12 - Gastroenterologia ,Dasabuvir ,HCV DAA ,Gastroenterology ,virus diseases ,Valine ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Hepatitis C ,Hepatology ,Combination ,030211 gastroenterology & hepatology ,medicine.drug ,medicine.medical_specialty ,Proline ,Lactams, Macrocyclic ,Hepatitis C virus genotype 1, Hepatitis C virus genotype 4, decompensated liver cirrhosis, antiviral therapy, dasabuvir, ombitasvir, paritaprevir ,03 medical and health sciences ,Drug Therapy ,Internal medicine ,medicine ,Decompensation ,Adverse effect ,business.industry ,Virology ,Ombitasvir ,Clinical trial ,chemistry ,Paritaprevir ,business - Abstract
Summary Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once daily and dasabuvir (250 mg) twice daily for 12 weeks (patients with HCV genotype 1b infection) or 24 weeks (patients with HCV genotype 1a infection). Patients with HCV genotype 4 infection were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once per day for 24 weeks. All patients were given weight-based ribavirin. The primary efficacy endpoint was sustained virological response at week 12 after the end of treatment (SVR12), analysed by intention-to-treat. Univariate and multivariate logistic regression analyses were used to identify baseline characteristics associated with SVR12. Adverse events were recorded throughout the study. Findings 728 (96%) of 762 patients with cirrhosis who were given ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin therapy for 12 or 24 weeks achieved SVR12. Logistic regression analyses identified that bilirubin concentrations of less than 2 mg/dL were associated with SVR12 (odds ratio [OR] 4·76 [95% CI 1·83–12·3]; p=0·001). 166 (23%) of 734 patients included in safety analyses had an adverse event. 25 (3%) patients discontinued treatment because of adverse events. Asthenia was the most commonly reported adverse event, occurring in 36 (5%) patients. Interpretation Our findings suggest that the safety and effectiveness of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin in patients with HCV genotype 1 or 4 infection and cirrhosis at high risk of decompensation in a real-life setting are similar to those reported in clinical trials. The concordance with clinical trials provides reassurance that the reported efficacy of this treatment in clinical trials will translate to its use in routine clinical practice. Funding Dipartimento Biomedico di Medicina Interna e Specialistica dell'Universita di Palermo.
- Published
- 2017
19. Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report.
- Author
-
Caviglia GP, Zorzi A, Rizzetto M, Mirandola M, Olivero A, and Carolo G
- Abstract
The reactivation of hepatitis B virus (HBVr) in patients undergoing pharmacological immunosuppression is a potentially fatal clinical event that may occur in patients with overt or occult HBV infection. The risk of HBVr is mainly determined by the type of immunosuppressive therapy and the HBV serologic profile, with a higher risk in patients positive for the hepatitis B surface antigen (HBsAg), and a lower risk in HBsAg-negative/antibodies to core antigen-positive subjects. Notably, a considerable proportion of patients experiencing HBVr showed a high degree of variability of the HBV S gene, possibly leading to immune escape mutants. These mutations, usually in the "a-determinant" of the HBsAg, can cause diagnostic problems and consequently hamper the appropriate management strategy of patients at risk of HBVr. Here, we describe a case of HBVr in a patient with a diagnosis of chronic myeloid leukemia and a previous history of kidney transplant, providing evidence of the potential usefulness of hepatitis B core-related antigen measurement in patients with HBV immune-escape mutants at risk of viral reactivation.
- Published
- 2021
- Full Text
- View/download PDF
20. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
- Author
-
Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, Pozzoni P, Giorgini A, Fabris P, Romano A, Lomonaco L, Puoti M, Vinci M, Gatti F, Carolo G, Zoncada A, Bonfanti P, Russo FP, Aghemo A, Soria A, Centenaro R, Maggiolo F, Rovere P, Pasin F, Paon V, Faggiano G, Vario A, Grossi G, Soffredini R, Carriero C, Paolucci S, Noventa F, Alberti A, Lampertico P, and Fagiuoli S
- Subjects
- Antiviral Agents administration & dosage, Antiviral Agents adverse effects, Drug Combinations, Drug Resistance, Viral, Female, Humans, Italy epidemiology, Male, Middle Aged, RNA, Viral isolation & purification, Retreatment methods, Risk Factors, Sustained Virologic Response, Treatment Outcome, Viral Nonstructural Proteins, Carbamates administration & dosage, Carbamates adverse effects, Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular etiology, Carcinoma, Hepatocellular pathology, Hepacivirus drug effects, Hepacivirus genetics, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic epidemiology, Hepatitis C, Chronic virology, Heterocyclic Compounds, 4 or More Rings administration & dosage, Heterocyclic Compounds, 4 or More Rings adverse effects, Liver Cirrhosis diagnosis, Liver Cirrhosis epidemiology, Liver Neoplasms epidemiology, Liver Neoplasms etiology, Liver Neoplasms pathology, Macrocyclic Compounds administration & dosage, Macrocyclic Compounds adverse effects, Sofosbuvir administration & dosage, Sofosbuvir adverse effects, Sulfonamides administration & dosage, Sulfonamides adverse effects
- Abstract
Background & Aims: Sofosbuvir/velpatasivr/voxilaprevir (SOF/VEL/VOX) is approved for retreatment of patients with HCV and a previous failure on direct-acting antivirals (DAAs), however real-life data are limited. The aim of this study was to assess the effectiveness and safety of SOF/VEL/VOX in a real-life setting., Methods: All consecutive patients with HCV receiving SOF/VEL/VOX between May-October 2018 in 27 centers in Northern Italy were enrolled. Bridging fibrosis (F3) and cirrhosis (F4) were diagnosed by liver stiffness measurement: >10 and >13 kPa respectively. Sustained virological response (SVR) was defined as undetectable HCV-RNA 4 (SVR4) or 12 (SVR12) weeks after the end-of-treatment., Results: A total of 179 patients were included: median age 57 (18-88) years, 74% males, median HCV-RNA 1,081,817 (482-25,590,000) IU/ml. Fibrosis stage was F0-F2 in 32%, F3 in 21%, F4 in 44%. HCV genotype was 1 in 58% (1b 33%, 1a 24%, 1nc 1%), 2 in 10%, 3 in 23% and 4 in 9%; 82% of patients carried resistance-associated substitutions in the NS3, NS5A or NS5B regions. Patients received SOF/VEL/VOX for 12 weeks, ribavirin was added in 22% of treatment schedules. Undetectable HCV-RNA was achieved by 74% of patients at week 4 and by 99% at week 12. Overall, 162/179 (91%) patients by intention to treat analysis and 162/169 (96%) by per protocol analysis achieved SVR12, respectively; treatment failures included 6 relapsers and 1 virological non-responder. Cirrhosis (p = 0.005) and hepatocellular carcinoma (p = 0.02) were the only predictors of treatment failure. Most frequent adverse events included fatigue (6%), hyperbilirubinemia (6%) and anemia (4%)., Conclusions: SOF/VEL/VOX is an effective and safe retreatment for patients with HCV who have failed on a previous DAA course in a real-life setting., Lay Summary: This is the largest European real-life study evaluating effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in a large cohort of consecutive patients with hepatitis C virus infection and a prior direct-acting antiviral failure, who were treated within the NAVIGATORE Lombardia and Veneto Networks, in Italy. This study demonstrated excellent effectiveness (98% and 96% sustained virological response rates at week 4 and 12, respectively) and an optimal safety profile of SOF/VEL/VOX. Cirrhosis and hepatocellular carcinoma onset were the only features associated with treatment failure., (Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
21. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
- Author
-
Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, and Alberti A
- Subjects
- Aged, Female, Humans, Incidence, Italy epidemiology, Male, Middle Aged, Prospective Studies, Risk Assessment methods, Risk Factors, Sustained Virologic Response, Treatment Outcome, Antiviral Agents therapeutic use, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular pathology, Hepacivirus drug effects, Hepacivirus isolation & purification, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic epidemiology, Liver Cirrhosis diagnosis, Liver Cirrhosis etiology, Liver Neoplasms diagnosis, Liver Neoplasms pathology
- Abstract
Background & Aims: Direct-acting antiviral agents (DAAs) are safe and effective in patients with hepatitis C. Conflicting data were reported on the risk of hepatocellular carcinoma (HCC) during/after therapy with DAAs. The aim of this study was to evaluate the incidence of newly diagnosed HCC and associated risk factors in patients with advanced hepatitis C treated with DAAs., Methods: The study is based on the NAVIGATORE platform, a prospectively recording database of all patients with hepatitis C receiving DAAs in the Veneto region of Italy. The inclusion criteria were: fibrosis stage ≥F3. The exclusion criteria were: Child-Turcotte-Pugh (CTP)-C, liver transplantation before DAAs, history or presence of HCC, follow-up <4 weeks after starting DAAs. A total of 3,917 out of 4,234 consecutive patients were included, with a mean follow-up of 536.2 ± 197.6 days., Results: Overall, HCC was diagnosed in 55 patients. During the first year, HCC incidence was 0.46% (95% CI 0.12-1.17) in F3, 1.49% (1.03-2.08) in CTP-A and 3.61% (1.86-6.31) in CTP-B cirrhotics; in the second year, HCC incidences were 0%, 0.2%, and 0.69%, respectively. By multivariate analysis, HCC was significantly associated with an aspartate aminotransferase to platelet ratio ≥2.5 (hazard ratio [HR] 2.03; 95% CI 1.14-3.61; p = 0.016) and hepatitis B virus infection (HR 3.99; 1.24-12.91; p = 0.021). Failure to achieve a sustained virological response was strongly associated with development of HCC (HR 9.09; 5.2-16.1; p = 0.0001). A total of 29% of patients with HCC had an aggressive tumor, often seen in the early phase of treatment., Conclusions: These data, obtained in a large, prospective, population-based study, indicate that in patients with advanced hepatitis C receiving DAAs, the risk of "de novo" hepatocarcinoma during the first year is not higher, and might be lower, than that of untreated patients. The risk further declines thereafter. Early hepatocarcinoma appearance may reflect pre-existing, microscopic, undetectable tumors., Lay Summary: Hepatocellular carcinoma is one of the complications of hepatitis C related cirrhosis. Treating patients with advanced hepatitis C with the new interferon-free direct-acting antiviral agents has been associated with improvement in liver function and survival, while more conflicting data have been reported regarding the risk of hepatocellular carcinoma. We report the results of a prospective population study on the incidence of newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with direct-acting antiviral agents, clearly indicating that the residual hepatocellular carcinoma risk is reduced and declines progressively with time after a sustained virological response. Development of a liver tumor during/after therapy was associated with known risk factors and with virological failure., (Copyright © 2018. Published by Elsevier B.V.)
- Published
- 2018
- Full Text
- View/download PDF
22. Does tenofovir increase efavirenz hepatotoxicity?
- Author
-
Lattuada E, Lanzafame M, Carolo G, Gottardi M, Concia E, and Vento S
- Subjects
- Adenine adverse effects, Adult, Alkynes, Antiretroviral Therapy, Highly Active adverse effects, Cyclopropanes, Female, Humans, Male, Middle Aged, Tenofovir, Adenine analogs & derivatives, Anti-HIV Agents adverse effects, Benzoxazines adverse effects, Chemical and Drug Induced Liver Injury, HIV Infections drug therapy, Organophosphonates adverse effects
- Published
- 2008
- Full Text
- View/download PDF
23. Human herpesvirus 8 cytoviraemia rebound in a patient with Kaposi's sarcoma after a short interruption of efficient antiretroviral therapy.
- Author
-
Parisi SG, Mazzi R, Sarmati L, Carolo G, Uccella I, Rianda A, Nicastri E, Concia E, and Andreoni M
- Subjects
- Antibodies, Viral blood, Disease Progression, Drug Administration Schedule, Herpesvirus 8, Human immunology, Humans, Leukocytes, Mononuclear virology, Male, Sarcoma, Kaposi etiology, Skin Neoplasms etiology, Viremia etiology, Acquired Immunodeficiency Syndrome complications, Antiretroviral Therapy, Highly Active, DNA, Viral blood, Herpesvirus 8, Human isolation & purification, Sarcoma, Kaposi virology, Skin Neoplasms virology, Viremia virology
- Published
- 2002
- Full Text
- View/download PDF
24. Prevalence trend and correlates of HHV-8 infection in HIV-infected patients.
- Author
-
Parisi SG, Sarmati L, Pappagallo M, Mazzi R, Carolo G, Farchi F, Nicastri E, Concia E, Rezza G, and Andreoni M
- Subjects
- Adult, Female, Humans, Male, Prevalence, Substance Abuse, Intravenous complications, AIDS-Related Opportunistic Infections epidemiology, Antibodies, Viral blood, HIV Infections complications, Herpesviridae Infections epidemiology, Herpesvirus 8, Human immunology
- Abstract
To assess the circulation of human herpesvirus (HHV)-8 infection over the years, two seroprevalence surveys were conducted, which tested sera from HIV-infected individuals recruited 10 years apart (206 individuals from 1986 to 1988 and 177 individuals from 1997 to 1998). For all patients, antibodies to hepatitis C virus (HCV), hepatitis B virus (HBV), and HHV-8 lytic and latent antigens were evaluated.HHV-8 seroprevalence was higher among individuals recruited in the 1990s (31.6% for anti-lytic, 8.5% for anti-latent antibodies) compared with similar findings in those seen in the late 1980s (14.6% and 3.4% for anti-lytic and anti-latent antibodies, respectively), with a twofold increase of the risk of HHV-8 infection. However, the increase was observed only among injecting drug users, whereas seroprevalence tended to slightly increase among those infected by sexual contact. At univariate analysis, time of recruitment and being homosexual men were factors associated with HHV-8 infection, an association that remained after adjusting for age. HBV infection was significantly associated with HHV-8 infection (odds ratio [OR], 2.2; 95% confidence interval [CI], 1.3-3.6), whereas those infected with HCV had a lower probability of having HHV-8 antibodies (OR, 0.3; 95% CI, 0.20-0.6). After controlling for age and gender, time of recruitment remained independently associated with HHV-8 infection among injecting drug users. In conclusion, HHV-8 seroprevalence appears to be increased during 10 years among HIV-infected injection drug users but not among homosexual men, who remain those at the highest risk of infection.
- Published
- 2002
- Full Text
- View/download PDF
25. Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS.
- Author
-
Mazzi R, Parisi SG, Sarmati L, Uccella I, Nicastri E, Carolo G, Gatti F, Concia E, and Andreoni M
- Subjects
- AIDS-Related Opportunistic Infections virology, Cidofovir, DNA, Viral blood, Disease Progression, Herpesvirus 8, Human drug effects, Humans, Sarcoma, Kaposi virology, Skin Neoplasms virology, Treatment Outcome, Viremia virology, AIDS-Related Opportunistic Infections drug therapy, Antiviral Agents therapeutic use, Cytosine analogs & derivatives, Cytosine therapeutic use, Herpesvirus 8, Human physiology, Organophosphonates, Organophosphorus Compounds therapeutic use, Sarcoma, Kaposi drug therapy, Skin Neoplasms drug therapy
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.